AbCellera Biologics Inc. (NASDAQ:ABCL)
| Market Cap | 3.37B+158.2% |
| Revenue (ttm) | 66.17M+101.3% |
| Net Income | -164.66M+0.6% |
| EPS | -0.54+3.6% |
| Shares Out | 305.38M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,406,131 |
| Open | 11.44 |
| Previous Close | 11.44 |
| Day's Range | 11.01 - 11.44 |
| 52-Week Range | 2.75 - 12.58 |
| Beta | 1.19 |
| Analysts | Buy |
| Price Target | 15.33(+38.73%) |
| Earnings Date | Nov 5, 2026 |
About ABCL
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$ABCL stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in ABCL holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ABCL's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ABCL Estimated quarterly lobbying spending
Source: U.S. Senate LDA
ABCL Revenue by Segment or Geography
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New ABCL patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ABCL from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in ABCL
| ETF | Est. Holding Size |
|---|---|
| IBBiShares Biotechnology ETF | $20.50M |
| CPAINorthern Lights Fund Trust III - Counterpoint Quantitative Equity ETF | $13.37M |
| IDNAiShares Genomics Immunology and Healthcare ETF | $6.59M |
| SPDWState Street SPDR Portfolio Developed World ex-US ETF | $6.55M |
| GWXState Street SPDR S&P International Small Cap ETF | $1.93M |
| ONEQFidelity Nasdaq Composite Index ETF | $1.55M |
Estimated from each fund’s disclosed top holdings × AUM
ABCL Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from ABCL’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score